Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4642 in Perioperative Treatment of Pancreatic Cancer
NCT07900789Phase 3Not yet recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2026
- Primary completion
- Nov 2030
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of HRS-4642 in pancreatic cancer (PC) (3 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Event-Free Survival. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
HRS-4642
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07900789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07900789.